T. Rowe Price holds 8.2% of Repligen (RGEN) common stock

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed an amended Schedule 13G reporting a significant ownership position in Repligen Corp. common stock. The firm reports beneficial ownership of 4,599,860 shares, representing 8.2% of the outstanding common stock as of December 31, 2025.

T. Rowe Price states it has sole voting power over 4,301,925 shares and sole dispositive power over 4,599,061 shares, with no shared voting or dispositive power. It certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Repligen.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

REPLIGEN CORP

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

759916109

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 759916109

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,301,925.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,599,061.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,599,860.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.2 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: REPLIGEN CORP
(b)	Address of issuer's principal executive offices: 41 SEYON STREET, BUILDING, SUITE 100, WALTHAM, MA, 02453
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 759916109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4599860
(b)	Percent of class: 8.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4301925
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4599061
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026

FAQ

What stake does T. Rowe Price hold in Repligen Corp (RGEN)?

T. Rowe Price Associates, Inc. reports beneficial ownership of 4,599,860 shares of Repligen common stock, representing 8.2% of the class as of December 31, 2025. This makes it a significant institutional holder under SEC reporting rules.

What voting power does T. Rowe Price report over Repligen (RGEN) shares?

T. Rowe Price reports sole voting power over 4,301,925 Repligen common shares and no shared voting power. This means it alone can vote these shares, while having no joint authority with other parties for voting decisions, according to the Schedule 13G/A filing.

How many Repligen (RGEN) shares can T. Rowe Price dispose of?

T. Rowe Price reports sole dispositive power over 4,599,061 Repligen common shares and no shared dispositive power. Dispositive power means it can decide if and when to sell or otherwise dispose of these shares on behalf of its clients.

Why did T. Rowe Price file this Schedule 13G/A for Repligen (RGEN)?

The filing updates T. Rowe Price’s beneficial ownership of Repligen common stock as of December 31, 2025, showing an 8.2% stake. It is required because the position exceeds 5%, triggering SEC disclosure obligations for institutional investors under Schedule 13G rules.

Is T. Rowe Price seeking control of Repligen Corp (RGEN)?

T. Rowe Price certifies the Repligen shares were acquired and are held in the ordinary course of business and not to change or influence control of the company. The filing expressly disclaims beneficial ownership for control purposes, consistent with a passive investment stance.

Who signed the T. Rowe Price Schedule 13G/A relating to Repligen (RGEN)?

The Schedule 13G/A was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., dated February 17, 2026. The signature certifies, after reasonable inquiry, that the information provided about Repligen share ownership is true, complete, and correct.